Morgan Stanley Global Healthcare Conference (Isis Pharmaceuticals, Inc) - Sep 11, 2012 - Anticipated initiation of P3 trials for scarring resulting from surgery in 2013
Anticipated new P3 trial • Fibrosis
|
|
EXC 001
-- -- --
Sure EXC OO1 is kind of a sleeper drug in our pipeline and it's a drug that is an example of part of our business strategy called our (inaudible) company strategy…… Pfizer bought the company which was very exciting and now we have Pfizer’s balance sheet and clinical acumen behind the drug, they are preparing for Phase III clinical trials now and plan to take the drug into Phase III clinical trials next year and scarring associated with surgery there is no competition, and it's potentially is large as a 4 billion market opportunity.
-- -- --
(IR8)
|